Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/08/2023 08:00 EST Earnings Call Q4 2022 -- -- --
02/08/2023 -- Results Q4 2022 -- 0.71 --
11/03/2022 -- Results Q3 2022 0.59 0.62 -4.22%
11/03/2022 08:00 EST Earnings Call Q3 2022 -- -- --
07/27/2022 -- Results Q2 2022 0.68 0.56 20.57%
07/27/2022 08:00 EST Earnings Call Q2 2022 -- -- --
05/03/2022 08:00 EST Earnings Call Q1 2022 -- -- --
05/03/2022 -- Results Q1 2022 0.55 0.55 0.18%
*Estimated Date/Time

Earnings

Next Report Date 02/08/2023
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2022
Beat/Miss Upgrade
Return Since 24.97%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Based in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers.
URL https://www.tevapharm.com
Investor Relations URL https://ir.tevapharm.com/
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Mid Cap/Value
Next Earnings Release Feb. 08, 2023
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Nov. 27, 2017

Dividends

Dividend Per Share (TTM) 0.00
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency Quarterly
Last Ex-Dividend Date Nov. 27, 2017
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2016
2017
2018
2019
2020
2021
2022
YTD
-43.20%
-46.01%
-18.63%
-36.45%
-1.53%
-16.99%
13.86%
17.98%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-18.11%
7.86%
9.88%
60.13%
-0.98%
1.50%
27.61%
32.40%
24.04%
-9.28%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-10.42%
-13.22%
--
--
--
--
--
--
-68.99%
29.46%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
34.24%
-7.31%
As of February 03, 2023.

Profile

Edit
Based in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers.
URL https://www.tevapharm.com
Investor Relations URL https://ir.tevapharm.com/
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Mid Cap/Value
Next Earnings Release Feb. 08, 2023
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Nov. 27, 2017

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
EIS 10.32M USD 6.60%
ISRA 3.513M USD 5.54%
PPH 19.32M USD 4.21%
BMPEX 1.617M USD 3.39%
MVISX 41.04M USD 3.09%
CHO208 136725.0 USD 1.85%
TAM003 971882.0 USD 1.83%
FGTMYX 145827.0 USD 1.46%
SQBIX 380041.0 USD 1.22%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter TEVA Tweets